Lisata Therapeutics (NASDAQ:LSTA) Given “Buy” Rating at HC Wainwright

by · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $15.00 price target on the stock.

Lisata Therapeutics Trading Up 5.3 %

Shares of Lisata Therapeutics stock opened at $3.18 on Wednesday. The stock has a market capitalization of $26.42 million, a price-to-earnings ratio of -1.29 and a beta of 1.21. Lisata Therapeutics has a twelve month low of $1.99 and a twelve month high of $3.83. The business’s 50 day simple moving average is $3.11 and its 200-day simple moving average is $3.11.

Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.14. During the same period last year, the business earned ($0.50) earnings per share. Sell-side analysts predict that Lisata Therapeutics will post -2.97 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA – Free Report) by 48.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

(Get Free Report)

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.

See Also